The 2021 revision of the World Health Organization (WHO) classification system for central nervous system tumors reclassified IDH-mutant glioblastoma as IDH-mutant astrocytoma, WHO grade 4. This evidence concerns the gene IDH2 and astrocytoma (excluding glioblastoma).